1-2 of 2
Keywords: bortezomib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 pathway via IκBα protein stabilization

Chuanjian Suo, Zeping Gui, Zijie Wang, Jiajun Zhou, Ming Zheng, Hao Chen, Shuang Fei, Min Gu, Ruoyun Tan
Journal: Clinical Science
Clin Sci (Lond) (2021) 135 (1): 53–69.
https://doi.org/10.1042/CS20201038
Published: 05 January 2021
...–mesenchymal transition. Bortezomib has been reported to prevent the progression of fibrosis in organs. We used rat renal transplantation model and human kidney 2 cell line treated with tumor necrosis factor-α (TNF-α) to examine their response to bortezomib. To explore the mechanism behind it, we assessed...
View article titled, <span class="search-highlight">Bortezomib</span> limits renal allograft interstitial fibrosis by inhibiting NF-κB&#x2F;TNF-α&#x2F;Akt&#x2F;mTOR&#x2F;P70S6K&#x2F;Smurf2 pathway via IκBα protein stabilization
Open the PDF for <span class="search-highlight">Bortezomib</span> limits renal allograft interstitial fibrosis by inhibiting NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 pathway via IκBα protein stabilization in another window
Includes: Supplementary data
Articles

In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline

Zuzana Pokorna, Eduard Jirkovsky, Marketa Hlavackova, Hana Jansova, Anna Jirkovska, Olga Lencova-Popelova, Petra Brazdova, Jan Kubes, Dita Sotakova-Kasparova, Yvona Mazurova, Michaela Adamcova, Lucie Vostatkova, Kristyna Holzerova, Frantisek Kolar, Tomas Simunek, Martin Sterba
Journal: Clinical Science
Clin Sci (Lond) (2019) 133 (16): 1827–1844.
https://doi.org/10.1042/CS20190139
Published: 27 August 2019
... were further supported by several in vitro studies on immature cardiomyocytes. In the present study, we investigated the toxicity of clinically used PIs alone (bortezomib (BTZ), carfilzomib (CFZ)) as well as their combinations with an ANT (daunorubicin (DAU)) in both neonatal and adult ventricular...
View article titled, In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline
Open the PDF for In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline in another window
Includes: Supplementary data